1. Home
  2. AGRZ vs BTAI Comparison

AGRZ vs BTAI Comparison

Compare AGRZ & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGRZ

Agroz Inc. Ordinary Shares

N/A

Current Price

$2.06

Market Cap

50.3M

ML Signal

N/A

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$2.01

Market Cap

49.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGRZ
BTAI
Founded
2020
2017
Country
Malaysia
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.3M
49.2M
IPO Year
2025
2018

Fundamental Metrics

Financial Performance
Metric
AGRZ
BTAI
Price
$2.06
$2.01
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
$32.80
AVG Volume (30 Days)
252.2K
578.0K
Earning Date
05-22-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.04
N/A
Revenue
$9,138,479.00
$752,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$416.40
P/E Ratio
$52.53
N/A
Revenue Growth
121.21
N/A
52 Week Low
$1.83
$1.17
52 Week High
$7.20
$9.26

Technical Indicators

Market Signals
Indicator
AGRZ
BTAI
Relative Strength Index (RSI) N/A 48.39
Support Level N/A $1.82
Resistance Level N/A $2.30
Average True Range (ATR) 0.00 0.18
MACD 0.00 0.03
Stochastic Oscillator 0.00 37.30

Price Performance

Historical Comparison
AGRZ
BTAI

About AGRZ Agroz Inc. Ordinary Shares

Agroz Inc is a vertically integrated agricultural technology (AgTech) company focused on designing, innovating, developing, building, operating and managing large, commercial-scale, industrial-grade indoor CEA vertical farms using CEA practices. Its mission is to improve food safety, food security, and sustainability for society by creating a reliable, accessible food supply through its AgTech products and services. CEA vertical farming is an agricultural method involving crop cultivation through vertically stacked layers in a controlled indoor environment. CEA practices are defined by growing produce in spaces where environmental conditions can be controlled and manipulated to match the needs of specific plants.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: